FANCD2 and colorectal carcinoma: A post-hoc analysis of metastatic CRC patients (n = 520) enrolled in the CALGB (Alliance)/SWOG 80,405 randomized phase III trial, performed by a next-generation sequencing approach, showed that patients treated with cytotoxic agents (i.e., FOLFOX or FOLFIRI) plus cetuximab, whose tumors harbored mutated FANCD2, had a worse overall survival compared with patients with wild-type FANCD2 tumors [97].